July 17th 2020
Daniel H. Ahn, DO, discusses the slew of actionable alterations that have emerged in colorectal cancer in recent years, including targeted therapies that are boosting survival outcomes.
July 16th 2020
Sander Bach, MD, PhD, discusses research examining circulating tumor DNA in colorectal cancer.
July 15th 2020
Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.
Sander Bach, MD, PhD, discusses ongoing research with circulating tumor DNA in colorectal cancer.
July 14th 2020
Sander Bach, MD, PhD, discusses the results of a systematic review of circulating tumor DNA in colorectal cancer.
July 13th 2020
Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.
July 8th 2020
Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.
July 7th 2020
Salvatore Siena, MD, provides an overview of the DESTINY-CRC01 trial in DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer.
July 6th 2020
Sander Bach, MD, PhD, discusses the rationale to conduct a systematic review of circulating tumor DNA in colorectal cancer.
July 3rd 2020
Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.
